Statin Use and Serum Lipid Levels Are Associated with Survival Outcomes after Surgery for Renal Cell Carcinoma

Urology

Volumn 86, Issue 6, 2015, Pages 1146-1152

  Haddad, Ahmed Q ^a,b   Jiang, Lai ^a,b   Cadeddu, Jeffrey A ^a,b   Lotan, Yair ^a,b   Gahan, Jeffrey C ^a,b   Hynan, Linda S ^a,b   Gupta, Neil ^a,b   Raj, Ganesh V ^a,b   Sagalowsky, Arthur I ^a,b   Margulis, Vitaly ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGED; BLOOD; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRIGLYCERIDES; YOUNG ADULT;

EID: 84955494987     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.09.015     Document Type: Article

References (31)

1. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
2. W.A. Freed-Pastor, H. Mizuno, Zhao X., and et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway Cell 148 2012 244 258
3. K. Gauthaman, C.Y. Fong, and A. Bongso Statins, stem cells, and cancer J Cell Biochem 106 2009 975 983
4. J. Woodard, A. Sassano, N. Hay, and L.C. Platanias Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma Clin Cancer Res 14 2008 4640 4649
5. M.R. Graaf, A.B. Beiderbeck, A.C. Egberts, D.J. Richel, and H.J. Guchelaar The risk of cancer in users of statins J Clin Oncol 22 2004 2388 2394
6. V. Khurana, G. Caldito, and M. Ankem Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans Urology 71 2008 118 122
7. Liu W., T.K. Choueiri, and E. Cho Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts Cancer 118 2012 797 803
8. D.M. Boudreau, Yu O., and J. Johnson Statin use and cancer risk: a comprehensive review Expert Opin Drug Saf 9 2010 603 621
9. P.F. Coogan, L. Rosenberg, and B.L. Strom Statin use and the risk of 10 cancers Epidemiology 18 2007 213 219
10. G.D. Friedman, E.D. Flick, N. Udaltsova, J. Chan, C.P. Quesenberry Jr, and L.A. Habel Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients Pharmacoepidemiol Drug Saf 17 2008 27 36
11. E.J. Jacobs, C.C. Newton, M.J. Thun, and S.M. Gapstur Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort Cancer Res 71 2011 1763 1771
12. J. Hippisley-Cox, and C. Coupland Individualising the risks of statins in men and women in England and Wales: population-based cohort study Heart 96 2010 939 947
13. R.J. Hamilton, D. Morilla, F. Cabrera, and et al. The association between statin medication and progression after surgery for localized renal cell carcinoma J Urol 191 2014 914 919
14. S.D. Kaffenberger, O. Lin-Tsai, K.L. Stratton, and et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma Urol Oncol 33 2015 21.e11 21.e17
15. B.R. Viers, R. Houston Thompson, S.P. Psutka, and et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy Urol Oncol 33 2015 e311 e388
16. S.K. Choi, Min G.E., S.H. Jeon, H.L. Lee, Chang S.G., and K.H. Yoo Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy Mol Clin Oncol 1 2013 365 368
17. S.F. Nielsen, B.G. Nordestgaard, and S.E. Bojesen Statin use and reduced cancer-related mortality N Engl J Med 367 2012 1792 1802
18. A. Schatzkin, R.N. Hoover, P.R. Taylor, and et al. Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey Lancet 2 1987 298 301
19. R.R. Williams, P.D. Sorlie, M. Feinleib, P.M. McNamara, W.B. Kannel, and T.R. Dawber Cancer incidence by levels of cholesterol JAMA 245 1981 247 252
20. J.C. Melvin, L. Holmberg, S. Rohrmann, M. Loda, and M. Van Hemelrijck Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses J Cancer Epidemiol 2013 2013 823849
21. M. Van Hemelrijck, H. Garmo, N. Hammar, and et al. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study Int J Cancer 130 2012 2118 2128
22. M. de Martino, C.V. Leitner, C. Seemann, and et al. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC) BJU Int 115 2015 397 404
23. R.L. Camp, M. Dolled-Filhart, and D.L. Rimm X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 2004 7252 7259
24. R. Khosravi-Far, A.D. Cox, K. Kato, and C.J. Der Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ 3 1992 461 469
25. R. Krysiak, W. Zmuda, and B. Okopien The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: a preliminary report Pharmacol Rep 66 2014 880 884
26. D. Wanders, E.P. Plaisance, and R.L. Judd Pharmacological effects of lipid-lowering drugs on circulating adipokines World J Diabetes 1 2010 116 128
27. M. von Eynatten, J.G. Schneider, S. Hadziselimovic, and et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes Diabetes Care 28 2005 754 755
28. L.M. Blanco-Colio, J.L. Martin-Ventura, C. Gomez-Guerrero, and et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk Eur J Pharmacol 586 2008 259 265
29. Zhang X.L., Liu M., Qian J., and et al. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials Br J Clin Pharmacol 77 2014 458 465
30. B.R. Viers, R. Houston Thompson, S.P. Psutka, and et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy Urol Oncol 15 2015 S1078 S1439
31. M.A. Brookhart, A.R. Patrick, C. Dormuth, and et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect Am J Epidemiol 166 2007 348 354